Showing 2501-2510 of 7016 results for "".
Beyond the Data: The National ALS Registry
https://reachmd.com/programs/grand-rounds-nation/beyond-data-national-als-registry/9530/Dr. John Iskander and Dr. Paul Mehta discuss the knowns and unknowns of ALS.Digital Developments to Help Validate Insurance at Check-In
https://reachmd.com/programs/clinicians-roundtable/digital-developments-to-help-validate-insurance-at-check-in/4338/Many of our practices could be more efficient at checking in patients, or perhaps more precise in our record keeping. Insurance claims denials and the process of fighting them can be one source of time-consuming, money-draining aggravation for any practice. But we may be seeing a trend toward technoState of Cancer Care in America from ASCO President Clifford Hudis, MD
https://reachmd.com/programs/focus-on-cancer/state-of-cancer-care-in-america-brfrom-asco-president-clifford-hudis-md/6948/Joining host Dr. Matt Birnholz is special guest, Dr. Clifford A. Hudis, President of the American Society of Clinical Oncology (ASCO) and Chief of the Breast Cancer Medicine Service and an attending physician at Memorial Sloan-Kettering Cancer Center. Dr. Hudis will provide an executive summary of tA Personalized Approach to Uncontrolled Asthma Management
https://reachmd.com/programs/on-the-frontlines-of-asthma/personalized-management-uncontrolled-asthma/56829/Despite significant advances in treatment, many patients with asthma continue to experience uncontrolled symptoms driven by gaps in diagnosis, treatment optimization, inhaler technique, environmental exposures, and underlying comorbidities. Join Dr. Steve Jackson and Dr. Sujith V. Cherian as they exVedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
https://reachmd.com/programs/Audioabstracts/vedolizumab-induction-and-maintenance-therapy-crohns-disease-patients-naive-or-who-have-failed-tumor/9537/Vedolizumab had increased efficacy over placebo in CD patients irrespective of TNF-α antagonist treatment history.Predictors of Emergency Department Use by Persons with Inflammatory Bowel Diseases: A Population-Based Study
https://reachmd.com/programs/Audioabstracts/predictors-emergency-department-use-persons-with-inflammatory-bowel-diseases-population-based-study/8566/Identified predictors of ED attendance and post-ED hospitalization could guide the optimization of outpatient IBD care.Nicotinamide for COVID-19 Recovery: Restoring Metabolic Balance
https://reachmd.com/programs/clinicians-roundtable/nicotinamide-for-covid-19-recovery-restoring-metabolic-balance/36410/Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
https://reachmd.com/programs/cme/chairpersons-perspective-novel-treatments-for-newly-diagnosed-ph-cml-cp-striking-the-balance-of-treatment-with-patient-goals-and-qol/28646/Join Dr. Jorge Cortes and learn about best practices for selecting optimal treatment plans for newly diagnosed Ph+ CML-CP.Advancing Care in ER+/HER2− ESR1m mBC: What EMERALD and Real-World Analyses Tell Us
https://reachmd.com/programs/medical-industry-feature/advancing-care-in-erher2-esr1m-mbc-what-emerald-and-real-world-analyses-tell-us/35866/Most patients with ER-positive, HER2-negative metastatic breast cancer receive endocrine therapy plus a CDK4/6 inhibitor as first-line treatment.1-5 While this is initially effective, most tumors eventually develop resistance to endocrine therapy—often driven by the development of ESR1 mutations6,7—Signaling for Sustained Change: Spotlight on the Potential of TKIs to Deliver Durable Control of Exudative Retinal Disease
https://reachmd.com/programs/cme/Signaling-for-Sustained-Change-Spotlight-on-the-Potential-of-TKIs-to-Deliver-Durable-Control-of-Exudative-Retinal-Disease/39934/Explore the clinical promise of TKIs in managing exudative retinal diseases with insights on mechanisms, delivery, trials, and patient selection.